

EVALUATION OF BOERHAAVIA DIFFUSA FOR HEPATOPROTECTIVE ACTIVITY IN EXPERIMENTAL WISTAR RATS

Shameela S^{*1}, Shamshad S², Indira Priyadarsini A³ and Lakshmi Devi K¹

¹ Department of Biochemistry, S.K.University, Ananthapur, Andhrapradesh, India.

² Department of Zoology, K.V.R.Government College for Women, Kurnool, Andhrapradesh, India.

³ Department of Botany, K.V.R. Government College for Women, Kurnool, Andhrapradesh, India.

*Corresponding Author Email: shameela325@gmail.com

ABSTRACT

Boerhaavia diffusa (Nyctaginaceae) is conventionally used in Indian Ayurvedic system to treat liver diseases. The present study was undertaken to investigate the protective role of ethanol extract of *B. diffusa* on hepatic antioxidant status and the levels of diagnostic markers in isoproterenol - induced hepatitis in rats. The Prior oral administration of *B. diffusa* extract [150 mg/kg bodyweight/day for 45 days] significantly ($P < 0.05$) restored the levels of diagnostic marker enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatinine kinase (CK) and gamma glutamyl transferase (GGT)] and Lipid peroxidation levels was decreased in liver tissues of experimental rats. Also, a significant ($P < 0.05$) increase in reduced glutathione (GSH) and the activities of glutathione dependent antioxidant enzymes [glutathione peroxidase (GPx), glutathione-S-transferase (GST) and glutathione reductase (GR)] and antiperoxidative enzymes [catalase (CAT) and superoxide dismutase (SOD)] were observed in the liver tissue. Anti-hepatotoxic potential of *B. diffusa* might be due to its antioxidant property and membrane stabilizing action.

KEY WORDS

Boerhaavia diffusa, isoproterenol, Hepatitis, antioxidants, lipid peroxidation

INTRODUCTION

Herbal drugs have gained importance and popularity in recent years because of their safety, efficacy and cost effectiveness. Almost 80% of the world population depends on traditional medicine which predominantly based on plant material ¹. Demand for medicinal plants is increasing in both developing and developed countries due to growing recognition of natural products. In India, of the 17,000 species of higher plants, 7,500 are known for medicinal uses. Recently, several plants of Indian origin have been found to possess medicinal properties with their beneficial effects in ailments like atherosclerosis, ischemia, cancer, diabetes and

liver dysfunction. More than 87 medicinal plants were used in different combinations in the preparation of 33 patented herbal formulations ². Only a small portion of the hepatoprotective plants as well as formulations used in traditional medicine are pharmacologically evaluated for their efficacy. Secondary metabolites, the complex substances that synthesizing in Plants are commonly referred to as phytochemicals. These Phytochemicals are biologically active compounds that have potential disease inhibiting capabilities. There are several antioxidants or plant phytochemicals which are known to improve the various damages caused by oxidative stress ^{3, 4}. A large number of plants and purified

natural products have been screened for a wide variety of clinical diseases including liver disease⁵. Hence, the medicinal values of these plants lie on their component phytochemicals, which produce definite physiological actions on the human body.

Boerhaavia diffusa, belonging to the family, Nyctaginaceae, is mainly a perennial herbaceous creeping weed of India (its traditional name is *Punarnava*) and of Brazil (known as *Erva tostão*) is widely used in traditional medicine⁶. The word punarnava literally means, one which renews the body, that is, which brings back the youth. Punarnava enjoys an important place among medicinal herbs in India since ancient times. Pharmacological studies have demonstrated that *B. diffusa* possesses anti-inflammatory⁷, diuretic⁸, antifibrinolytic⁹, anticonvulsant¹⁰ and antibacterial properties¹¹, which makes it a very useful medicinal plant. Various parts of *Boerhaavia diffusa* are used for the treatment of numerous disorders in different parts of India. The roots are reputed to be diuretic and laxative and are given for the treatment of anasarca, ascites and jaundice¹². The same hepatoprotective activity was also reported in the aerial parts of *B. diffusa*¹³. Further experimental studies also evidenced a beneficial activity of the *Punarnava* root for the treatment of the jaundice^{14, 15}.

Hepatitis is a major public health problem worldwide, responsible for considerable morbidity and mortality from chronic liver disease¹⁶. Developing countries like India are also struggling to manage the impact of hepatitis along with the growing burden of obesity, Type II diabetes, hypertension and coronary heart disease¹⁷. The major abnormalities noticed in hepatitis are lipidemia, peroxidation and loss of plasma membrane integrity. There is an urgent need for the clinical development of safe and non-toxic cytoprotective agents for the adequate

management of hepatitis. A better understanding of the processes involved in hepatitis has stimulated the search for new drugs, which could limit the drug-induced hepatic injury.

Liver is the largest organ in human body and the principal site for intense metabolism and excretion¹⁸. It has a surprising role in the maintenance, performance and regulating the homeostasis of the body. The major functions of the liver are carbohydrate, protein and fat metabolism, detoxification, blood coagulation, immunomodulation, secretion of bile and storage of vitamins. It is involved with almost all the biochemical pathways responsible for growth, fight against disease, nutrient supply, energy provision and reproduction¹⁹. Liver diseases are among the most serious ailment²⁰. They may be classified as acute or chronic hepatitis (inflammatory liver diseases), hepatosis (non inflammatory diseases) and cirrhosis (degenerative disorder resulting in fibrosis of the liver). Liver diseases are mainly caused by toxic chemicals (certain antibiotics, chemotherapeutics, peroxidised oil, aflatoxin, carbon-tetrachloride, chlorinated hydrocarbons, etc.). Most of the hepatotoxic chemicals damage liver cells mainly by inducing lipid peroxidation and other oxidative damages in liver. Malondialdehyde (MDA), the end product of lipid peroxidation, is an important marker for assessment of oxidative status. The body has a protective mechanism against these free radicals in the form of antioxidant scavenging system which comprises of enzymatic and non enzymatic defense mechanisms. These include superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST) and reduced glutathione (GSH). The imbalance between oxidative stress and antioxidant defense mechanism underlies the etiopathogenesis of various diseases²¹. The ALT, AST and ALP activity levels were largely used as most common

biochemical markers to evaluate liver injury^{22, 23}. The rise in serum levels of SGPT, SGOT, ALP and CK has been attributed to the damaged structural integrity of the liver, because they are cytoplasmic in location and released into circulation during cellular damages.

Isoproterenol hydrochloride (ISPH), a synthetic catecholamine, was administered in the present study, is generally serves as a standard model to study the beneficial effect of many drugs on cardiac function. ISPH causes severe stress in the myocardium and cause necrosis in the heart muscle. ISPH-induced myocardial necrosis showed membrane permeability alterations, which bring about the loss of function and integrity of myocardial membranes^{24, 25}. There is no study reported on isoproterenol incuded toxicity in liver tissue. Hence, the present study was carried out to evaluate the hepatoprotective activity of ethanolic extract of *B. diffusa* in isoproterenol induced hepatotoxicity.

Materials and Method

Plant Material:

The whole plant of fresh *Boerhaavia diffusa* was collected from the Bramhadevum village of Anantapur district, Andhrapradesh, was used for extraction with ethanol which was already described in our earlier paper²⁶.

Experimental Animals:

In this experiment twenty four healthy male albino Wistar strains rats, 3 months of age, weighing 150 – 190g were procured from sri venkateswara enterprises, Bangalore, India. Selected rats were acclimatized for a period of two weeks in laboratory animal house and maintained under standard conditions of temperature $27 \pm 2^{\circ}\text{C}$, relative humidity of $60 \pm 5\%$ and 12: 12 hour light: dark cycle prior to experimentation. The animals were fed with standard pellet diet and water ad libitum. The study was approved by Animal Ethics Committee

of S.K. University, Anantapur (Reg. No 470/01/a/CPCSEA, dt.24th Aug 2001).

Drug treatment protocol:

After acclimatization, the rats were divided into four groups of 6 rats each. Group I rats served as the control and were injected with 20% Dimethyl sulfoxide for 45 days through oral intubation. Group II animals were injected with 20% Dimethyl sulfoxide for 45 days through oral intubation and administrated of $85\text{mg IKg}^{-1}\text{body wt day}^{-1}$, i. p for 2 days for the induction of hepatotoxicity for last 2 days of experimental period. Group III rats injected with 150 mg of Ethanolic extract from whole plant of *B.diffusa* dissolved in 20 % DMSO administered /Kg body weight/day for 45 days through oral intubation. Group IV animals were injected with ethanolic extract of *B.diffusa* at the above dosage for 45 days and then injected with isoproterenol [$85\text{mg IKg}^{-1}\text{body wt day}^{-1}$, i. p] for 2 days in the end of the experiment period.

At the end of the experimental period, i.e., 24 h after last injection of isoproterenol, the experimental animals were sacrificed, and blood was collected for the separation of serum. The liver tissue was excised immediately and washed with chilled isotonic saline. Then the tissue was homogenized in ice-cold 0.1 M Tris-HCl buffer, pH 7.2 and centrifuged and tissue homogenates were used for various biochemical analysis.

Lipid peroxidative extent was measured by the formation of malondialdehyde (MDA) by using the method of Okhawa²⁷. The diagnostic marker enzymes such as LDH, AST, ALT, ALP was estimated by Teitz method²⁸, using Robonik Diagnostic Kit, CK by Roasli method²⁹ and GGT by young method³⁰. Reduced Glutathione was estimated by Ellman's method³¹. Glutathione dependent antioxidant enzymes like GPX was estimated by Nakamura method³², GST by Habig method³³, GSR by pinto and Bartley method³⁴ and the peroxidative enzymes like catalase by

Beers and Sizer method³⁵ and Superoxide dismutase by Soon and Tan method³⁶.

Statistical analysis

Statistical analysis was performed by one way analysis of variance (ANOVA) followed by Duncan's Multiple Range Test (DMRT). The results were expressed as mean $\pm$ S.E.M for rats in each group. Values of $P < 0.05$ were considered as significant.

RESULTS & DISCUSSION

Liver diseases represent a major global health problem that still has no cure in modern medicine. Developing countries like India are also struggling to manage the impact of hepatitis along with the growing burden of obesity, Type II diabetes, hypertension and coronary heart disease³⁷. Some of the traditional plants used for treatment of liver disorders provided useful therapeutic agents. The major abnormalities noticed in hepatitis are lipidemia, peroxidation and loss of plasma membrane integrity.

The increase in MDA level in liver suggests enhanced lipid peroxidation leading to tissue damage and failure of antioxidant defence mechanisms to prevent formation of excessive

free radicals. It is now generally accepted that lipid peroxidation and its product play an important role in liver, kidney, heart and brain toxicity³⁸. Table I represents the effect of BDEEWP on the levels of myocardial LPO marker MDA and amount of reduced glutathione (GSH) in liver tissues of control and ISPH administered rats. The content of MDA, in the liver was elevated significantly ($P < 0.05$) by 61.5% and the GSH is decreased significantly ($P < 0.05$) by 51.47 % in the ISPH administered group when compared to normal control group. Animals treated with BDEEWP followed by ISPH injection showed significant ($P < 0.05$) decrease in MDA levels by 78.36% and increase in GSH levels by 94.51%. There is no significant difference between the control and BDEEWP alone treated rats i.e. in Group I and III. Glutathione is one of the abundant tripeptide non-enzymatic biological antioxidants present in the liver³⁹. Depletion of GSH results in enhanced lipid peroxidation and excessive lipid peroxidation can cause increased GSH consumption as observed in the present study, which was restored by the pretreatment with *B.diffusa*.

Table: I levels of GSH and LPO in the liver tissue of Control and Experimental Rats

	CONTROL	ISPH	CON+BDEEWP	ISPH+BDEEWP
GSH	38.54 $\pm$ 0.09 ^a	18.71 $\pm$ 0.10 ^d	41.47 $\pm$ 0.15 ^c	37.46 $\pm$ 0.17 ^b
LPO	18.35 $\pm$ 0.18 ^a	29.72 $\pm$ 0.15 ^b	18.69 $\pm$ 0.12 ^a	20.81 $\pm$ 0.24 ^b

Values are mean $\pm$ S.E.M for six rats in each group. Values in the same row not sharing a common superscript (a-c) differ significantly $P < 0.05$ with each other.

Antioxidants play an important role in providing protection of humans against infection and degenerative diseases⁴⁰. Data presented in table II indicates the activities of glutathione dependent antioxidant enzymes (GPX, GST and GR) and antiperoxidative enzymes (SOD and CAT) in liver of control and experimental rats. There is a significant ($P < 0.05$) decrease in the activities of

glutathione dependent enzymes, GPX, GST and GR by 46.19%, 35.50% and 25.20% and a significant ($P < 0.05$) decrease is observed in the antiperoxidative enzymes, SOD, CAT by 38.61% and 52.94% in livers of ISPH administered rats compared to controls. Pretreatment with BDEEWP increased the activities of antioxidant enzymes by 65.93%, 32.87%, 15.50%, 57.99 and

74.04% respectively for GPX, GST, GR, CAT and SOD. However, BDEEWP treatment alone does not show much significant change compared with the control groups of liver. Previous studies have shown that natural antioxidant molecules impart stabilization to cell membranes in relation to the

degree of their free radical scavenging ability^{41, 42, 43}. Hence, it is possible that likewise *B. diffusa* may also prolong the viability of liver cell membranes from ISPH-induced necrotic damage by its membrane stabilizing action.

Table: II Effect of BDEEWP on Hepatic Tissue Antioxidant Enzyme Levels in Control and Experimental Rats

ANTIOXIDANT ENZYMES	CONTROL	ISPH	CON+BDEEWP	ISPH+BDEEWP
Glutathione Peroxidase	76.84±0.15 ^a	41.35±0.13 ^c	76.51±0.22 ^a	68.61±0.17 ^b
Glutathione – S- Transferase	26.60±0.34 ^a	17.16±0.07 ^c	26.55±0.22 ^a	22.80±0.22 ^b
Glutathione Reductase	35.57±0.21 ^a	26.60±0.34 ^c	34.37±0.20 ^a	30.73±0.17 ^b
Sodium dismutase	38.07±0.20 ^a	23.37±0.15 ^b	37.13±0.21 ^a	36.93±0.18 ^a
Catalase	49.56±0.08 ^a	23.32±0.15 ^d	47.35±0.27 ^b	40.59±0.21 ^c

Values are mean ± S.E.M for six rats in each group. Values in the same row not sharing a common superscript (a-c) differ significantly P<0.05 with each other.

Data in the table III represents the levels of the biochemical marker enzymes such as AST, ALT, ALP, LDL, CK and GGT in liver tissues of the control and experimental rats. A significant decrease ($P < 0.50$) 31.05%, 40.56%, 42.96%, 35.32%, 59.16% and 12.46% was observed in the liver tissues of ISPH induced rats compared to the normal rats. The present observation is in agreement with earlier reported studies⁴⁴, which have shown that the amount of diagnostic marker enzymes present in plasma is directly proportional to the number of necrotic cells present in the liver tissue. Oral pre-treatment of

BDEEWP restores the activities of marker enzymes in liver tissues (33.55%, 64.61%, 70.46%, 41.27%, 79.80% and 78.42%) of ISPH administered rats. There is no significant difference between the control and BDEEWP alone treated rats i.e. in Group I and III. Decrease in liver AST, ALT, ALP, LDL, CK, and GGT has been attributed to the damaged structural integrity of the liver, because they are cytoplasmic in location and released into serum after cellular damage⁴⁵. Thereby increased in the concentrations of serum diagnostic markers were reported earlier in our previous paper⁴⁶.

Table: III Effect of BDEEWP treatment and pre-treatment on liver tissue marker enzymes in Control and Experimental groups

MARKER ENZYME	CONTROL	ISPH	CON+BDEEWP	ISPH+BDEEWP
AST	72.43±0.24 ^a	49.94±0.29 ^c	71.75±0.19 ^a	68.73±0.34 ^b
ALT	120.65±1.37 ^a	71.72±0.41 ^c	120.41±0.16 ^a	103.34±0.47 ^b
ALP	362.04±1.80 ^a	206.50±0.25 ^c	364.49±0.44 ^a	316.10±0.65 ^b
LDH	1269.07±7.06 ^a	820.80±0.77 ^d	1233.59±2.92 ^b	1005.81±0.52 ^c
CK	228.31±0.34 ^a	93.23±0.15 ^d	233.65±0.53 ^b	201.03±0.27 ^c
GGT	7.63±0.01 ^a	6.68±0.01 ^c	7.64±0.01 ^a	7.42±0.01 ^b

Values are mean ± S.E.M for six rats in each group. Values in the same row not sharing a common superscript (a-c) differ significantly P<0.05 with each other. All the Values are expressed as U/mg protein.

CONCLUSION

The results of the present study indicate that the prior administration of *B. diffusa* at 150 mg/kg body weight/day for 45 days prevents the isoproterenol induced hepatitis in rats. In the present study, the prior treatment with *B. diffusa* significantly ($P < 0.05$) decreased all these ISPH - induced alterations in the activities of antioxidant enzymes, marker enzymes and maintained the rats at a near normal status. The overall hepatoprotective effect of *B. diffusa* is probably related to a counteraction of free radicals by its antioxidant property, or by its membrane stabilizing action, or to its ability to maintain near to normal status the activities of free radical enzymes and the level of GSH, which protect hepatocellular membrane against oxidative damage by decreasing lipid peroxidation.

REFERENCES

1. WHO, Regional office for the western pacific, research guidelines for evaluating the safety and efficacy of herbal medicines, Manila, WHO, (1993).
2. Vitaglione, P., Morisco, F., Caporaso, N., Fogliano, V., Dietary antioxidant compounds and liver health. Crit Rev Food Sci Nutr. X 44, 575-86, (1999).
3. Khan MS, Khan A, Iqbal J. Effect of dietary tocotrienols on infection and inflammation induced lipoprotein oxidation in hamsters. Int J Pharm and Pharmaceut Sci.; 3(3): 277-284, (2011a).
4. Khan MS, Khan MKA, Siddiqui MH, Arif JM. An in vivo and in silico approach to elucidate the Tocotrienol-mediated fortification against infection and inflammation induced alterations in antioxidant defense system. Eur Rev Med Pharm Sci.; 15(8): 916, (2011b).
5. Subramonium A and Pushpangadan P, Development of liver diseases, Indian J Pharmacol, 31, 166-175, (1999).
6. Hiruma ICA, Gracioso JS, Bighetti EJ, Germosen RL, Souza BAR, The juice of fresh leaves of *Boerhaavia diffusa* L. (Nyctaginaceae) markedly reduces pain in mice. J. Ethnopharmacol., 71: 267-74, (2000).
7. Bhalla, T.N., Gupta, M.B., Sheth, P.K., and Bhargava, K.P. Antiinflammatory activity of *Boerhaavia diffusa*. Indian Journal of Physiology and Pharmacology; 12:37, (1968).
8. Gaitonde, B.B., Kulkarni, H.J., and Nabar, S.D. Diuretic activity of punarnava (*Boerhaavia diffusa*). Bulletins of the Haffkine Institute (Bombay, India); 2:24, (1974).
9. Jain, G.K. and Khanna, N.M. Punarnavoside: A new antifibrinolytic agent from *Boerhaavia diffusa* L. Indian Journal of Chemistry; 28b:163-166, (1989).
10. Adesina, S.K. Anticonvulsant properties of the roots of *Boerhaavia diffusa*. Quarterly Journal of Crude Drug Research; 17:84-86, (1979).
11. Olukoya, D.K., Tdika, N. and Odugbemi, T. Antibacterial activity of some medicinal plants from Nigeria. Journal of Ethnopharmacology; 39:6, (1993).
12. Rawat AKS, Mehrotra S, Tripathi SC and Shome U., Hepatoprotective activity of *Boerhaavia diffusa* L. roots a popular Indian ethnomedicine., Journal of Ethnopharmacology, 56, 61-66 (1997).
13. Chakraborti, K.K. and Handa, S.S. Antihepatotoxic investigations of *Boerhaavia diffusa* L. Indian Drugs; 27: 161-166 (1989).
14. Singh, V. and Pandey, R.P. Medicinal plantlore of the tribals of eastern Rajasthan. Journal of Economic and Taxonomic Botany; 137-147, (1980).
15. Gopal, G.V. and Shah, G.L. Some folk medicinal plants used for jaundice in Gujarat, India. Journal of Research Education in Indian Medicine; 4: 44-49 (1985).
16. Lau, D. T. and Membreno, F. E. Antiviral therapy for treatment-native hepatitis B virus patients. Gastroenterol. Clin. North Am. 33: 581-599, (2004).
17. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol; 38:215-22 (2003).
18. Ram, V. J. Herbal preparations as a source of hepatoprotective agents. Drug News and

- Perspective, ISSN 0214-0934 Vol 14, No.6, (2001). pp. 353-363.
19. Ward, F. M. & Daly, M. J. Hepatic Disease. In: Clinical Pharmacy and Therapeutics, R. Walker & C. Edwards (Eds.), 195- 212, Churchill Livingstone, New York., (1999).
 20. Samir S, Hepatoprotective Natural Products, 2(5), 110-111, (2001).
 21. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem; 64:97-112, (1995).
 22. Kozar, E., Evans, S., Barr, J., Greenberg, R. , Soriano I, Bulkowstein, M, Petrov, I., Chen-Levi, Z., Barzilay, B. and Berkovitch, M.: Br J Clin Pharmacol., 55(3): 234- 40, (2003).
 23. Girish, C., Koner, B.C., Jayanthi, S., Rao, K.R., Rajesh, B. and Pradhan, S.C.: Indian J Med Res., 129(5): 569- 578, (2009).
 24. Todd GL, Cullan GE, Cullan GM. Isoproterenol-induced myocardial necrosis and membrane permeability alterations in the isolated perfused rabbit heart. Exp Mol Pathol; 33:43-54, (1980).
 25. McCord JM. Free radicals and myocardial ischemia. Free Radic Biol Med; 4:9-14 (1988).
 26. S. Shameela, S. Shamshad, A. Indira Priyadarsini, K. Lakshmi Devi. Cardioprotective Effect of Ethanolic Extract of Boerhaavia diffusa (BDEEWP) on Isoproterenol-induced Myocardial Infarction in Wistar Rats. International Science Congress Association, ISBN:978-93-84648-32-9, 120-13, (2014).
 27. Ohkawa H, Ohishi N and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem, 95: 351-358, (1979).
 28. Teitz NW. In Fundamentals of clinical chemistry, WB Saunders and company, Philadelphia; 602-603, (1976).
 29. Rosalki SB, McIntyre N. Biochemical investigations in the management of liver disease. Oxford textbook of clinical hepatology, 2nd ed. New York; Oxford university press; 503-521, (1999).
 30. Young DS. Effects of drugs on clinical laboratory tests, 4th edition, AACC press, (1995).
 31. Ellmans. Tissue sulphydryl. Arch Biochem Biophys. 82: 70-77, (1959)
 32. Nakamura W., Hosoda S. and Hayashi K., Purification and properties of rat liver glutathione peroxidase. Biochim. biophys. Acta 358, 251-261, (1974).
 33. Habig WH, Pabst MJ, Jakoby WB: Glutathione-S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 249: 7130-9, (1974)
 34. Pinto RE, Bartley W., The effect of age and sex on glutathione reductase and glutathione peroxidase activities and on aerobic glutathione oxidation in rat liver homogenates. Biochem J. 112: 109-15, (1969).
 35. Beers R Jr, Sizer JW. Spectrophotometric method for measuring breakdown of H₂O₂ catalase. J Biol Chem. 195: 133-140, (1952).
 36. Soon, Y.Y. and B.K.H. Tan. Evaluation of the Hypoglycemic and Antioxidant Activities of Morinda officinalis in Streptozotocin-induced Diabetic Rats. Singapore Med J 43: 77-85, (2002)
 37. Aggarwal R, Ghoshal UC. Hepatitis B vaccination policy for India: is selective vaccination an option?. Indian J. Gastroenterol. 23: 2-4, (2004).
 38. Lakshmi B, Tilak JC, Adhikari S, Devasagayam TPS, Janardhanan KK. Inhibition of lipid peroxidation induced by Gamma-radiation and AAPH in rat liver and brain mitochondria by mushrooms. Curr Sci; 88: 484-88, (2005).
 39. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem. Biol. Interact. 111-112: 1-14, (1998).
 40. Gupta LB, Anju P and Najma ZB, Protective effects of sodium orthovanadate in diabetic reticulocytes and ageing red blood cells of Wistar rats. J. Biosci. 29, 1, 73-79 (2004).
 41. Sabeena Farvin KH, Anandan R., Hari Senthil Kumar S, Shiny KS, Sankar TV, Thankappan TK., Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. Pharmacological Res. 50: 231-236, (2004).
 42. Ganesan B, Rajesh R, Anandan R, Dhandapani N., Biochemical Studies on the Protective effect of betaine on mitochondrial function in experimentally induced myocardial infarction in rats. J. Health Science; 53: 671-681, (2007).
 43. B. Meena, R. Anbin Ezhilan, R. Rajesh, A. Sheik Hussain, B. Ganesan, R. Anandan. Antihepatotoxic

- potential of *Sargassum polycystum* (Phaeophyceae) on antioxidant defense status in Dgalactosamine- induced hepatitis in rats. African Journal of Biochemistry Research Vol.2 (2), pp. 051-055, (2008).
44. Anandan R, Devaki T., Hepatoprotective effect of *Picrorrhiza kurroa* on tissue defence system in D-galactosamine-induced hepatitis in rats. *Fitoterapia*; 70: 54-57, (1999).
45. Salli, R., Tredger, J.M., William, R., Drugs and the liver: Part I, Testing liver functions. *Biopharm Drug Dis.* 12, 251-259 (1991).
46. Shameela.S, Shamshad.S, Indira Priyadarsini.A, John Paul.M, Lakshmi Devi.K., Hypolipidemic and Anti Inflammatory Activity of *Boerhaavia Diffusa* in Isoproterenol-Induced Myocardial Infarcted Rats. *Int J Pharm Bio Sci* , 6(2): (P) 1 – 10, (2015).



***Corresponding Author:**
shameela325@gmail.com